Arrayit corporation(otc bb: Aryc.ob)

[KittyCat]

Market Pulse Breaking News Alert for Wednesday, September 2, 2009: ARYC -- Arrayit Lands Patent for Population Scale Diagnostics

ATLANTA, GA -- (Marketwire) -- 09/02/09 --

Market Pulse News Alert for this AM, Stocks to Watch are: Arrayit Corporation (OTCBB: ARYC), Novavax Inc. (NASDAQ: NVAX), AVI Biopharma Inc. (NASDAQ: AVII) and BioNeutral Group Inc. (OTCBB: BONU).

Investors need to be watching Arrayit Corporation (OTCBB: ARYC) this AM! Arrayit Corporation is engaged in the development, manufacture, and marketing of life science technologies and integrated systems for the analysis of genetic variation, biological function, and diagnostics.

Arrayit offers a product line of approximately 650 tools to 2,500 laboratories worldwide. The company's products include microarrayers, microarray scanners, DNA and protein microarrays, microarray printing, microarray substrates and slides, microarray instruments, amplification and labeling, purification kits, microarray hardware, buffers and solutions, microarray cleanrooms, books and software, CGH microarrays, and microarray platforms. Arrayit's worldwide business position leverages the company's widely used patented microarray manufacturing platform and revolutionary VIP(TM) genotyping technology. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. The company is also involved in the import, export, and distribution of industrial and food grade chemicals for plastics, fertilizers, and green energy applications.

It has research collaboration with The Parkinson's Institute of Sunnyvale to discover biomarkers for Parkinson's disease. ARYC recently announced that it is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus. The 2009 swine flu outbreak has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic elements from both the swine and human influenza viruses, allowing direct human-to-human transmission without the need for agricultural contact. Arrayit is an exciting and innovative public company that strives to increase shareholder equity by inventing, developing, manufacturing and supplying sophisticated life sciences products and services to an extensive customer base spanning 50 countries. Arrayit is a leader in the field of molecular diagnostics with patented technology that allows the screening and monitoring of up to 80,000 patient samples on a single microscope slide, rather than testing one patient per slide as is currently practiced.

Their corporate philosophy is embodied by a highly skilled, multidisciplinary team of investors, business professionals, scientists, engineers and executive and support staff who place shareholder value, product quality, customer service and price competitiveness as their highest priorities. Arrayit empowers decisive strategic advantage and large return on investment for their customers in the research, pharmaceutical, diagnostic, and health care markets! ARYC just had excellent news out in a press release before today's opening bell announcing that they landed a patent for population scale diagnostics in the world's most populous country the People's Republic of China! The company also said China is expected to be a diagnostics business bonanza for them! Investors should be watching this one closely!

Arrayit Coporation (OTCBB: ARYC), proprietary life sciences technology leader, announces that on August 31st, 2009 the company received a patent certificate from the most populous country on the planet, the People's Republic of China. The patent covers Dr. Mark Schena's microarray methods of genotyping multiple patient samples, commonly referred to as Arrayit's "Variation Identification Platform(TM)" (VIP) technology.

Arrayit VIP is a universal platform for deoxyribonucleic acid (DNA)-based genetic screening, testing, diagnostics, genotyping and single nucleotide polymorphism (SNP) analysis. In simple terms, VIP allows clinical laboratories to examine DNA samples from as many as 80,000 individuals with a single test rather than relying on limited "one test per patient" techniques. China is the world's largest marketplace, and Arrayit sees nearly unlimited diagnostics sales potential in this emerging region.

"VIP is well suited for analyzing DNA from large populations in a rapid, affordable and highly accurate manner," states Rene Schena, CEO and co-founder of Arrayit Corp. "We look forward to introducing VIP technology to the People's Republic."

VIP is a versatile testing platform that allows scientists and medical doctors to screen mass numbers of humans for the presence of genetic markers, as well as for viral and bacterial infections. VIP also empowers the analysis of livestock, poultry and crop plants. This is a very critical aspect of VIP, as it allows the tracing of disease origins from agents such as the H1N1 flu strain. VIP could clearly become the gold standard for genetic and infectious disease detection and management.

Arrayit has obtained VIP patents in a long list of countries, and the China issuance represents a significant milestone for the company.

Stocks acting well as of late include: Novavax Inc. (NASDAQ: NVAX), AVI Biopharma Inc. (NASDAQ: AVII) and BioNeutral Group Inc. (OTCBB: BONU).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies.

MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated, in connection with its profile of Arrayit Corporation, fifty thousand shares of Arrayit Corporation's common stock by a third party shareholder. Additionally, MP bought for its own account in the open market, forty thousand shares of Arrayit Corporation's shares for a total purchase price of twenty three thousand eight hundred twenty dollars. To date, MP has sold twenty thousand shares of stock in Arrayit Corporation for proceeds totaling nine thousand six hundred thirty six dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services.

Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact:

Market Pulse

800.290.8935

Email Contact

[KittyCat]

Posted in wrong forum - mybad! - mods. please move? - thanks!

[KittyCat]

Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip
Apr 30, 2009 8:00:00 AM

SUNNYVALE, Calif., April 30 /PRNewswire-FirstCall/ -- Arrayit Corporation (OTC Bulletin Board: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced today that it is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus.

The Arrayit test will allow researchers and clinicians to detect the presence of the virus in infected patients and livestock and to distinguish the threatening mutated strain from less harmful variants in humans and swine. Using its state-of-the-art manufacturing facility, Arrayit plans to begin mass production of its test kits over the next several weeks. The H1N1 test kits will be sent to the Centers for Disease Control (CDC) for validation, then sold for emergency use by licensed clinics, laboratories and other health care organizations worldwide.

The 2009 swine flu outbreak has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic elements from both the swine and human influenza viruses, allowing direct human-to-human transmission without the need for agricultural contact. The dangerous 2009 strain has little immunity in the human population, resistance to several common anti-viral drugs, and has caused serious illness and death.

Department of Health and Human Services spokesperson said, "In the event of an emerging pandemic, the CDC-IRR (Influenza Reagent Resource) will serve as a source of reagents for qualified laboratories to provide additional support. During a pandemic, laboratories will play a critical role in detecting and confirming initial cases, characterizing viruses, monitoring the progression of the pandemic, and selecting vaccine strains. Scientists around the world are concerned that the influenza virus could one day mutate and acquire the properties needed to quickly spread between people, resulting in a pandemic."

Arrayit's unique microarray platform allows the design, manufacture and distribution of H1N1 chip technology quickly and inexpensively, owing to the Company's unique and patented contact printing technology, versatile system architecture, and broad customer base. "Our team is able to leverage the most sophisticated and accurate gene testing available on the market today to rapidly and affordably bring this H1N1 flu chip test to market," said Rene Schena, Chief Executive Officer of Arrayit Corporation.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit Arrayit Corporation - The Microarray Company for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.

Contact:
Arrayit Corporation
Tel: 408-744-1331
Email: investorinfo@arrayit.com
Web:

SOURCE Arrayit Corporation

[greencat]

ARYC Chart